Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11490998 | PMC |
| http://dx.doi.org/10.1186/s13024-024-00769-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comorbidities in early-onset sporadic versus presenilin-1 mutation-associated Alzheimer disease dementia: Evidence for dependency on Alzheimer disease neuropathological changes.
J Neuropathol Exp Neurol
December 2024
Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, AZ, United States.
Article Synopsis
Autoantibody profiles in Alzheimer´s, Parkinson´s, and dementia with Lewy bodies: altered IgG affinity and IgG/IgM/IgA responses to alpha-synuclein, amyloid-beta, and tau in disease-specific pathological patterns.
J Neuroinflammation
December 2024
Centre for Neuroscience and Stereology, Department of Neurology, Bispebjerg and Frederiksberg Hospital, Copenhagen University Hospital, Nielsine Nielsens Vej 6B, Entrance 11B, 2. floor, Copenhagen, NV, DK-2400, Denmark.
Article Synopsis
- Alzheimer's (AD) and Parkinson’s disease (PD) are major neurodegenerative disorders characterized by specific protein aggregations, with Alzheimer’s linked to amyloid-beta (Aβ) and tau, and Parkinson’s associated with alpha-synuclein (αSyn).
- The research examined naturally occurring autoantibodies (nAbs), including IgG, IgM, and IgA, in patients with AD, PD, and dementia with Lewy bodies (DLB), revealing altered levels and affinities of these antibodies compared to healthy controls.
- Findings indicated that AD patients had lower high-affinity anti-αSyn and anti-Aβ IgGs, while DLB patients showed increased anti-αSyn IgG but decreased Ig
Therapeutic Potential of Ramalin Derivatives with Enhanced Stability in the Treatment of Alzheimer's Disease.
Molecules
November 2024
Division of Polar Life Sciences, Korea Polar Research Institute, Incheon 21990, Republic of Korea.
Alzheimer's disease (AD) remains a significant public health challenge with limited effective treatment options. Ramalin, a compound derived from Antarctic lichens, has shown potential in the treatment of AD because of its strong antioxidant and anti-inflammatory properties. However, its instability and toxicity have hindered the development of Ramalin as a viable therapeutic agent.
View Article and Find Full Text PDFVirus-like Particles-Based Vaccine to Combat Neurodegenerative Diseases.
Curr Pharm Biotechnol
October 2024
Division of Applied Biomedical Science and Biotechnology, School of Health Science, International Medical University.
Neurodegenerative diseases are regarded as gradual, incurable conditions with an insidious onset. Alzheimer's disease (AD) and Parkinson's disease (PD) are two of the most prevalent neurodegenerative diseases reported globally. Developing effective treatment strategies for neurodegenerative diseases has remained a primary objective and a huge challenge for researchers.
View Article and Find Full Text PDFComparing anti-tau antibodies under clinical trials and their epitopes on tau pathologies.
Mol Neurodegener
October 2024
ADEL Institute of Science & Technology (AIST), ADEL, Inc, Seoul, Korea.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!